Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCIT-HDM in house dust mite-allergic children with allergic rhinitis with or without asthma
TCTR20261031027Phase 3Not yet recruiting
- Start
- Sep 2026
- Countries
- 1
01
Overview
Phase 3, open-label trial in allergic rhinitis (AR) and asthma (2 arms), sponsored by None. Primary endpoints: Interleukin-4 concentration, Interleukin-5 concentration and 1 more. Planned start Sep 2026; status: not yet recruiting.
02
Conditions
allergic rhinitis (AR)asthma
Beyond the preview
Go deeper on TCTR20261031027.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20261031027.